Entasis Therapeutics Announces the Appointment of Elizabeth Keiley as General Counsel
April 16 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced the appointment of
Elizabeth Keiley as General Counsel. Ms. Keiley’s primary
responsibility will be to manage the Company’s legal activities and
to lead its compliance and corporate governance functions.
Manos Perros, Chief Executive Officer of
Entasis, commented, “Elizabeth brings invaluable experience and a
strong track record to this role, as Entasis progresses into
late-stage clinical development and potentially commercialization.
Elizabeth’s depth of experience and her proven expertise in
corporate governance, compliance, intellectual property strategy
and licensing, make her uniquely qualified to help our team as we
continue to develop our company.”
“This is an exciting time to be joining Entasis
as the Company prepares to transition into a commercial-stage
company with multiple late-stage clinical candidates,” said Ms.
Keiley. “I aim to utilize my experience in navigating the legal and
regulatory requirements for development and commercialization of
Entasis’ innovative pathogen-specific, multi-drug resistant
antimicrobial therapies.”
Ms. Keiley is a seasoned attorney and has served
in several in-house counsel positions for various healthcare
companies. Prior to joining Entasis, Ms. Keiley was Senior Vice
President, General Counsel at Oxford Immunotec, a U.K.-based
global, high-growth diagnostics company focused on developing and
commercializing proprietary assays for immunology and infectious
disease. Previously, Ms. Keiley served as the Assistant General
Counsel of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., the
world’s largest pure-play orthopedic device manufacturer. Earlier,
she was a trial lawyer and partner with Wildman, Harrold, Allen
& Dixon in Chicago, Illinois where she represented clients in a
wide variety of commercial disputes and transactions.
Ms. Keiley earned her bachelor’s degree in
psychology and philosophy from Boston College and a J.D. from
Loyola University School of Law.
About Entasis
Entasis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel antibacterial products to treat serious infections caused
by multidrug-resistant Gram-negative bacteria. Entasis’
targeted-design platform has produced a pipeline of product
candidates, including ETX2514SUL (targeting A. baumannii
infections), zoliflodacin (targeting Neisseria gonorrhoeae), and
ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information, visit
www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis
Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactLee RothThe Ruth
Group646-536-7012lroth@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024